NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

Hepatocellular Carcinoma Clinical Trial

Official title:

A Phase I Clinical Trial of NKG2D-based CAR T-cells Injection for Subjects With Relapsed/Refractory NKG2DL+ Solid Tumors

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04270461
• Other study ID #: JiujiangUH
• Status: Withdrawn
• Phase: Phase 1
• Start date: March 17, 2020
• Est. completion date: October 17, 2020

Study information

• Verified date: October 2020
• Source: Jiujiang University Affiliated Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

Description:

The preclinical study clarified that NKG2D-based CAR-T cells showed strong cytotoxicity against NKG2DL+ cell lines in vitro as well as a therapeutic effect against NKG2DL+ cell xenografts in vivo. In addition, the data also demonstrated the safety of NKG2D-based CAR-T therapy. NKG2D-based CAR-T represent a potentially effective and safety therapeutic approach for patient with relapsed/refractory NKG2DL+ solid tumors. In this trial, the investigators researched the safety of administering NKG2D-based CAR-T which generated with CD8 hinge region and transmembrane region, 4-1BB costimulatory region and CD3 zeta region. The investigators also assessed that disease response was determined within the context of a phase I trial.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 17, 2020
• Est. primary completion date: October 17, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria:

1. Men or women=18 years old,

2. Patient with NKG2DL+ cell tumors confirmed by pathology and histology,

3. Fail or unwilling to receive first-line treatment,

4. Disease must be measurable according to the corresponding guidelines,

5. Main organs function normally and meet following requirements:

Routine blood index(No Blood transfusion within 14 days) 1)HB=90g/L; 2)ANC=1.5×109/L; 3)PLT=75×109/L; Serum biochemicals index 1) BIL <1.5 upper normal limit (ULN); 2) ALT and AST<2.5×ULN; In the case of liver metastasis, ALT and AST<5×ULN; 3) Serum Cr=1×ULN, endogenous creatinine clearance=50ml/min (Cockcroft-Gault formula); 4) ECOG physical condition score: 0-2

6. Expected survival time =3 months,

7. Patient with adequate bone marrow reserve, hepatic and renal functions,

8. No other uncontrolled diseases such as lung, kidney and liver infection before enrollment,

9. Women of child-bearing age must undergo a negative pregnancy test (serum or urine) within 7 days prior to enrollment and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last dose; men should agree to contraception during the observation period and within 8 weeks of the last dose,

10. Patients voluntarily participated in this trial and sign the informed consent form,

11. Patients with compliance and expected to follow up the efficacy and adverse reactions as required by the protocol.

Exclusion criteria:

1. Pregnant or lactating women,

2. Patients who need to use systemic steroids at the same time,

3. Under following treatment conditions currently: 1) during the other anti- tumor clinical observation period within 14 days before blood collection; 2) patient has not recovered from acute side effects of the previous treatment;

4. Receive radiotherapy within 4 weeks before enrollment,

5. Patients who received any other cell therapy before,

6. Patients with unqualified T cell amplification efficiency,

7. Uncontrolled symptoms or other illnesses, including but not limited to infection, congestive heart failure, unstable angina, arrhythmia, psychosis,

8. Patients with severe acute allergic reactions,

9. Patients who have received other cell therapies,

10. Other serious conditions that may limit patient's participation in the study.

Detailed disease specific criteria exist and can be discussed with contacts listed below.

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Colon Cancer
• Glioblastoma
• Hepatocellular Carcinoma
• Medulloblastoma

Intervention

Biological:
• NKG2D-based CAR T-cells
Autologous genetically modified anti-NKG2DLs CAR transduced T cells

Locations

Country	Name	City	State
China	Affiliated hospital of jiujiang university	Jiujiang	Jiangxi

Sponsors (2)

Lead Sponsor	Collaborator
Jiujiang University Affiliated Hospital	KAEDI

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with severe cytokine release syndrome(CRS) as a Measure of Safety and Tolerability.	The severe CRS post KD-025 CAR-T cells treatment will be evaluated and the maximum tolerated dose will be determined.	0 to 28 days post infusion
Primary	Copies numbers of CAR	Copies numbers of CAR in peripheral blood (PB)	1 year post infusion
Secondary	overall survival (OS)	For all subjects, overall survival refers to the period from being included in the test group to death caused by any reason	2 years post infusion
Secondary	Progress Free Survival (PFS)	Progress Free Survival after administration	2 years post infusion
Secondary	Duration of response, (DoR)		2 years post infusion